Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders

Bone Marrow Transplantation

Volumn 24, Issue 10, 1999, Pages 1089-1093

  Foot, A B M ^a   Veys, P A ^b   Gibson, B E S ^c  

^a BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

Bone marrow transplantation; Itraconazole; Mycoses; Neutropenia; Pediatrics

Indexed keywords

AMPHOTERICIN; ITRACONAZOLE; VINCRISTINE;

ABDOMINAL PAIN; ADOLESCENT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD DISEASE; CANCER CHEMOTHERAPY; CANDIDIASIS; CHILD; CLINICAL TRIAL; CONSTIPATION; CONVULSION; DIARRHEA; DRUG TOLERABILITY; FEMALE; FEVER; FOOD INTAKE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEUTROPENIA; NEUTROPHIL; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; VOMITING;

EID: 0032710996     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702023     Document Type: Article

References (23)

1. Costoli V, Holzel H, Veys P et al. Invasive aspergillosis in immunocompromised patients. 67th British Paediatric Association Annual Meeting, 1996.
2. Jantunen E, Ruutu P, Niskanen L et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997; 19: 801-808.
3. Verweij PE, Denning DW. Diagnostic and therapeutic strategies for invasive aspergillosis. Semin Resp Crit Care Med 1997; 18; 203-215.
4. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608-615.
5. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12: 308-329.
6. Goa KL, Barradell LB. Fluconazole: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995; 50: 658-690.
7. De Beule K. Itraconazole: pharmacology, clinical experience and future development. Int J Antimicrob Agents 1996; 6: 175-181.
8. Tricot G, Joosten E, Boogaerts MA et al. Ketoconazole vs itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two non-randomized studies. Rev Infect Dis 1987; 9: S94-S99.
9. Vreugdenhil G, Van Dijke BJ, Donnelly JP et al. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double-blind, placebo controlled study. Leak Lymphoma 1993; 11: 353-358.
10. Prentice AG, Warnock DW, Johnson SAN et al. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother 1994: 34: 247-252.
11. Prentice AG, Warnock DW, Johnson SAN et al. Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. J Antimicrob Chemother 1995: 36: 657-663.
12. Morgenstern GR, Prentice AG, Prentice HG et al. A randomised controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancy. Br J Haematol 1999; 105: 901-911.
13. Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New Engl J Med 1992; 326: 845-851.
14. Winston DJ, Chandrasekar PH, Lazarus HM et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Ann Intern Med 1993; 118: 495-503.
15. Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-1552.
16. Ellis ME, Clink H, Ernst P et al. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 1994; 13: 3-11.
17. Yamac K, Senol E, Haznedar R. Prophylactic use of fluconazole in neutropenic cancer patients. Postgrad Med J 1995; 1: 284-286.
18. Mouy R, Veber F, Blanche S et al. Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease. J Ped 1994; 125: 998-1003.
19. Levron JC, Chwetzoff E, Lappareau Gallot A et al. Pharmacokinetic study of itraconazole oral solution during chronic treatment in neutropenic children. Janssen Research Foundation: Beerse, 1997.
20. Boogaerts MA, Verhoef GE, Zachee P et al. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989; 32: 103-108.
21. Grant SM, Clissold SP. Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989; 37: 310-344.
22. Prentice AG, Warnock DW, Morgenstern GR et al. Serum concentrations of itraconazole in neutropenic patients receiving itraconazole/cyclodextrin solution. Blood 1997; 90: 545a.
23. Association of the British Pharmaceutical Industry. Oncovin data sheet. ABPI Compendium of Data Sheets and Summaries of Product Characteristics 1998-99. Datapharm Publications Ltd: London, 1998, pp 653-654.